CommercialCoverageMedium impact
06.02.17h, Serodiagnosis of Inflammatory Bowel Disease (IBD) and the Prometheus® IBD sgi Diagnostic™ Test
Independence Blue Cross·Gastroenterology, Internal Medicine, Family Medicine·Pharmacy
Effective date
Jul 9, 2025
We identified it
Jun 19, 2026
Summary
IBX Commercial policy 06.02.17h regarding Serodiagnosis of Inflammatory Bowel Disease and the Prometheus IBD sgi Diagnostic Test has been reissued with updates. This is a fresh pharmacy category policy that may affect billing and coverage for IBD diagnostic testing services.
Action Required
By July 9, 2025: Billing team should review the updated IBX Commercial policy 06.02.17h for any changes to coverage, prior authorization requirements, or billing procedures for IBD serodiagnosis and Prometheus IBD sgi Diagnostic tests. Access the full policy at the provided URL to identify specific billing impacts and update procedures accordingly.